Placebo influences on dyskinesia in Parkinson's disease
Identifieur interne : 000285 ( France/Analysis ); précédent : 000284; suivant : 000286Placebo influences on dyskinesia in Parkinson's disease
Auteurs : Christopher G. Goetz [États-Unis] ; Eugene Laska [États-Unis] ; Christine Hicking [Allemagne] ; Philippe Damier [France] ; Thomas Müller [Allemagne] ; John Nutt [États-Unis] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2008-04-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Clinical trial, Dyskinesia, Dyskinesias (complications), Dyskinesias (diagnosis), Dyskinesias (drug therapy), Humans, Multicenter Studies as Topic (statistics & numerical data), Nervous system diseases, Odds Ratio, Organic Chemicals (adverse effects), Organic Chemicals (therapeutic use), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson disease, Parkinson's disease, Placebo, Placebo Effect, Prognosis, Randomized Controlled Trials as Topic (statistics & numerical data), Sarizotan, dyskinesias, placebo, randomized clinical trials, sarizotan.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Organic Chemicals.
- chemical , therapeutic use : Antiparkinson Agents, Organic Chemicals.
- complications : Dyskinesias, Parkinson Disease.
- diagnosis : Dyskinesias.
- drug therapy : Dyskinesias, Parkinson Disease.
- physiopathology : Parkinson Disease.
- statistics & numerical data : Multicenter Studies as Topic, Randomized Controlled Trials as Topic.
- Humans, Odds Ratio, Placebo Effect, Prognosis.
Abstract
Clinical features that are prognostic indicators of placebo response among dyskinetic Parkinson's disease patients were determined. Placebo‐associated improvements occur in Parkinsonism, but responses in dyskinesia have not been studied. Placebo data from two multicenter studies with identical design comparing sarizotan to placebo for treating dyskinesia were accessed. Sarizotan (2 mg/day) failed to improve dyskinesia compared with placebo, but both treatments improved dyskinesia compared with baseline. Stepwise regression identified baseline characteristics that influenced dyskinesia response to placebo, and these factors were entered into a logistic regression model to quantify their influence on placebo‐related dyskinesia improvements and worsening. Because placebo‐associated improvements in Parkinsonism have been attributed to heightened dopaminergic activity, we also examined the association between changes in Parkinsonism and dyskinesia. Four hundred eighty‐four subjects received placebo treatment; 178 met criteria for placebo‐associated dyskinesia improvement and 37 for dyskinesia worsening. Older age, lower baseline Parkinsonism score, and lower total daily levodopa doses were associated with placebo‐associated improvement, whereas lower baseline dyskinesia score was associated with placebo‐associated worsening. Placebo‐associated dyskinesia changes were not correlated with Parkinsonism changes, and all effects in the sarizotan group were statistically explained by the placebo‐effect regression model. Dyskinesias are affected by placebo treatment. The absence of correlation between placebo‐induced changes in dyskinesia and Parkinsonism argues against a dopaminergic activation mechanism to explain placebo‐associated improvements in dyskinesia. The magnitude and variance of placebo‐related changes and the factors that influence them can be helpful in the design of future clinical trials of antidyskinetic agents. © 2007 Movement Disorder Society
Url:
- https://api.istex.fr/document/26A53AAFCA642D9FC0D0DC629121E408271C161E/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689363
DOI: 10.1002/mds.21897
Affiliations:
- Allemagne, France, États-Unis
- District de Darmstadt, Hesse (Land), Illinois, Midi-Pyrénées, Oregon, État de New York
- Darmstadt, Nantes, Toulouse
- Université Toulouse III - Paul Sabatier, Université de Toulouse
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000342
- to stream Istex, to step Curation: 000342
- to stream Istex, to step Checkpoint: 001246
- to stream Pmc, to step Corpus: 000024
- to stream Pmc, to step Curation: 000024
- to stream Pmc, to step Checkpoint: 000432
- to stream PubMed, to step Corpus: 002364
- to stream PubMed, to step Curation: 002364
- to stream PubMed, to step Checkpoint: 002141
- to stream Ncbi, to step Merge: 001F95
- to stream Ncbi, to step Curation: 001F95
- to stream Ncbi, to step Checkpoint: 001F95
- to stream Main, to step Merge: 003268
- to stream PascalFrancis, to step Corpus: 001284
- to stream PascalFrancis, to step Curation: 001A35
- to stream PascalFrancis, to step Checkpoint: 001137
- to stream Main, to step Merge: 003745
- to stream Main, to step Curation: 002690
- to stream Main, to step Exploration: 002690
- to stream France, to step Extraction: 000285
Links to Exploration step
ISTEX:26A53AAFCA642D9FC0D0DC629121E408271C161ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Placebo influences on dyskinesia in Parkinson's disease</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name></author><author><name sortKey="Laska, Eugene" sort="Laska, Eugene" uniqKey="Laska E" first="Eugene" last="Laska">Eugene Laska</name></author><author><name sortKey="Hicking, Christine" sort="Hicking, Christine" uniqKey="Hicking C" first="Christine" last="Hicking">Christine Hicking</name></author><author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name></author><author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name></author><author><name sortKey="Nutt, John" sort="Nutt, John" uniqKey="Nutt J" first="John" last="Nutt">John Nutt</name></author><author><name sortKey="Warren Olanow, C" sort="Warren Olanow, C" uniqKey="Warren Olanow C" first="C." last="Warren Olanow">C. Warren Olanow</name></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><country>France</country><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Russ, Hermann" sort="Russ, Hermann" uniqKey="Russ H" first="Hermann" last="Russ">Hermann Russ</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:26A53AAFCA642D9FC0D0DC629121E408271C161E</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.21897</idno><idno type="url">https://api.istex.fr/document/26A53AAFCA642D9FC0D0DC629121E408271C161E/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000342</idno><idno type="wicri:Area/Istex/Curation">000342</idno><idno type="wicri:Area/Istex/Checkpoint">001246</idno><idno type="wicri:doubleKey">0885-3185:2008:Goetz C:placebo:influences:on</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689363</idno><idno type="RBID">PMC:2689363</idno><idno type="wicri:Area/Pmc/Corpus">000024</idno><idno type="wicri:Area/Pmc/Curation">000024</idno><idno type="wicri:Area/Pmc/Checkpoint">000432</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">002364</idno><idno type="wicri:Area/PubMed/Curation">002364</idno><idno type="wicri:Area/PubMed/Checkpoint">002141</idno><idno type="wicri:Area/Ncbi/Merge">001F95</idno><idno type="wicri:Area/Ncbi/Curation">001F95</idno><idno type="wicri:Area/Ncbi/Checkpoint">001F95</idno><idno type="wicri:doubleKey">0885-3185:2008:Goetz C:placebo:influences:on</idno><idno type="wicri:Area/Main/Merge">003268</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:08-0247739</idno><idno type="wicri:Area/PascalFrancis/Corpus">001284</idno><idno type="wicri:Area/PascalFrancis/Curation">001A35</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001137</idno><idno type="wicri:doubleKey">0885-3185:2008:Goetz C:placebo:influences:on</idno><idno type="wicri:Area/Main/Merge">003745</idno><idno type="wicri:Area/Main/Curation">002690</idno><idno type="wicri:Area/Main/Exploration">002690</idno><idno type="wicri:Area/France/Extraction">000285</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Placebo influences on dyskinesia in Parkinson's disease</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Laska, Eugene" sort="Laska, Eugene" uniqKey="Laska E" first="Eugene" last="Laska">Eugene Laska</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>New York University School of Medicine, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Nathan Kline Institute, Orangeburg, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Hicking, Christine" sort="Hicking, Christine" uniqKey="Hicking C" first="Christine" last="Hicking">Christine Hicking</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Merck KGaA, Darmstadt</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Darmstadt</settlement></placeName></affiliation></author><author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Centre Hospitalo‐universitaire de Nantes, Centre d'Investigation Clinique, Nantes</wicri:regionArea><placeName><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Ruhr University, Bochum</wicri:regionArea><wicri:noRegion>Bochum</wicri:noRegion><wicri:noRegion>Bochum</wicri:noRegion></affiliation></author><author><name sortKey="Nutt, John" sort="Nutt, John" uniqKey="Nutt J" first="John" last="Nutt">John Nutt</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Oregon Health Sciences University, Portland, Oregon</wicri:regionArea><placeName><region type="state">Oregon</region></placeName></affiliation></author><author><name sortKey="Warren Olanow, C" sort="Warren Olanow, C" uniqKey="Warren Olanow C" first="C." last="Warren Olanow">C. Warren Olanow</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mount Sinai School of Medicine New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Toulouse University Hospital, INSERM Clinical Investigation Center, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Russ, Hermann" sort="Russ, Hermann" uniqKey="Russ H" first="Hermann" last="Russ">Hermann Russ</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Merck KGaA, Darmstadt</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Darmstadt</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-04-15">2008-04-15</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="700">700</biblScope><biblScope unit="page" to="707">707</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">26A53AAFCA642D9FC0D0DC629121E408271C161E</idno><idno type="DOI">10.1002/mds.21897</idno><idno type="ArticleID">MDS21897</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Clinical trial</term><term>Dyskinesia</term><term>Dyskinesias (complications)</term><term>Dyskinesias (diagnosis)</term><term>Dyskinesias (drug therapy)</term><term>Humans</term><term>Multicenter Studies as Topic (statistics & numerical data)</term><term>Nervous system diseases</term><term>Odds Ratio</term><term>Organic Chemicals (adverse effects)</term><term>Organic Chemicals (therapeutic use)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Placebo</term><term>Placebo Effect</term><term>Prognosis</term><term>Randomized Controlled Trials as Topic (statistics & numerical data)</term><term>Sarizotan</term><term>dyskinesias</term><term>placebo</term><term>randomized clinical trials</term><term>sarizotan</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Organic Chemicals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Organic Chemicals</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Dyskinesias</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesias</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Multicenter Studies as Topic</term><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Odds Ratio</term><term>Placebo Effect</term><term>Prognosis</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term><term>Essai clinique</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Placebo</term><term>Sarizotan</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Clinical features that are prognostic indicators of placebo response among dyskinetic Parkinson's disease patients were determined. Placebo‐associated improvements occur in Parkinsonism, but responses in dyskinesia have not been studied. Placebo data from two multicenter studies with identical design comparing sarizotan to placebo for treating dyskinesia were accessed. Sarizotan (2 mg/day) failed to improve dyskinesia compared with placebo, but both treatments improved dyskinesia compared with baseline. Stepwise regression identified baseline characteristics that influenced dyskinesia response to placebo, and these factors were entered into a logistic regression model to quantify their influence on placebo‐related dyskinesia improvements and worsening. Because placebo‐associated improvements in Parkinsonism have been attributed to heightened dopaminergic activity, we also examined the association between changes in Parkinsonism and dyskinesia. Four hundred eighty‐four subjects received placebo treatment; 178 met criteria for placebo‐associated dyskinesia improvement and 37 for dyskinesia worsening. Older age, lower baseline Parkinsonism score, and lower total daily levodopa doses were associated with placebo‐associated improvement, whereas lower baseline dyskinesia score was associated with placebo‐associated worsening. Placebo‐associated dyskinesia changes were not correlated with Parkinsonism changes, and all effects in the sarizotan group were statistically explained by the placebo‐effect regression model. Dyskinesias are affected by placebo treatment. The absence of correlation between placebo‐induced changes in dyskinesia and Parkinsonism argues against a dopaminergic activation mechanism to explain placebo‐associated improvements in dyskinesia. The magnitude and variance of placebo‐related changes and the factors that influence them can be helpful in the design of future clinical trials of antidyskinetic agents. © 2007 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>France</li><li>États-Unis</li></country><region><li>District de Darmstadt</li><li>Hesse (Land)</li><li>Illinois</li><li>Midi-Pyrénées</li><li>Oregon</li><li>État de New York</li></region><settlement><li>Darmstadt</li><li>Nantes</li><li>Toulouse</li></settlement><orgName><li>Université Toulouse III - Paul Sabatier</li><li>Université de Toulouse</li></orgName></list><tree><country name="États-Unis"><region name="Illinois"><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name></region><name sortKey="Laska, Eugene" sort="Laska, Eugene" uniqKey="Laska E" first="Eugene" last="Laska">Eugene Laska</name><name sortKey="Laska, Eugene" sort="Laska, Eugene" uniqKey="Laska E" first="Eugene" last="Laska">Eugene Laska</name><name sortKey="Nutt, John" sort="Nutt, John" uniqKey="Nutt J" first="John" last="Nutt">John Nutt</name><name sortKey="Warren Olanow, C" sort="Warren Olanow, C" uniqKey="Warren Olanow C" first="C." last="Warren Olanow">C. Warren Olanow</name></country><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Hicking, Christine" sort="Hicking, Christine" uniqKey="Hicking C" first="Christine" last="Hicking">Christine Hicking</name></region><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name><name sortKey="Russ, Hermann" sort="Russ, Hermann" uniqKey="Russ H" first="Hermann" last="Russ">Hermann Russ</name></country><country name="France"><noRegion><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name></noRegion><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000285 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000285 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:26A53AAFCA642D9FC0D0DC629121E408271C161E
|texte= Placebo influences on dyskinesia in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |